Aldeyra Therapeutics (ALDX) said Thursday it received meeting minutes from the US Food and Drug Administration regarding the potential resubmission of its new drug application for reproxalap to treat dry eye disease.
The company requested clarification of the meeting minutes from the FDA and plans to seek a Type D meeting to discuss the potential NDA resubmission.
Aldeyra expects the Type D meeting to be held by the end of Q3 2026, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments